Eli Lilly reported a robust third quarter with revenue up 38.6% to $24.4 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized growth beyond weight-loss drugs, highlighting advances in immunology, oncology, and neuroscience. Analysts expect 15% revenue growth and 37% EPS growth in 2027, with shares potentially reaching $1,700 if the company maintains momentum and expands its oncology and other drug portfolios. Key upcoming milestones include new drug approvals and a global launch of oral GLP-1 in 2027.
Eli Lilly shares are trading at USD 1,399.00 on Pluang, showing a slight decline of 0.88% in the past day. As of Nov 03, 2026 20:11 WIB, the stock holds a market cap of $1.26 trillion with an 80% buy order activity on the platform.
The AI-driven bull market faces challenges as investors rotate from high-spending tech stocks like Nvidia to traditionally defensive stocks such as Walmart and Eli Lilly. Despite strong earnings in some tech sectors, the Nasdaq-100 and semiconductor ...
Eli Lilly reported strong recent financial results with solid revenue growth and robust margins, even raising its guidance. However, signs of slowing revenue growth in the near future could impact margins and temper enthusiasm. Despite this, Eli Lill...
Eli Lilly, having reached a $1.146 trillion market cap largely due to weight-loss drugs Mounjaro and Zepbound, is now showing strong growth potential in oncology, immunology, and neuroscience sectors, with Q2 revenue from these areas up 121% year ove...
Eli Lilly reported strong third-quarter results with a 39% increase in revenue to $24.4 billion, fueled by successful drug franchises like Mounjaro and Zepbound. The company’s growth is becoming more diversified with new products such as Foundayo, Re...
